Apolipoprotein E-derived peptides block α7 neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 2, 2006, Pages 835-842

  Gay, Elaine A ^a   Klein, Rebecca C ^a   Yakel, Jerrel L ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BUNGAROTOXIN; ALPHA2BETA2 NICOTINIC RECEPTOR; ALPHA4BETA2 NICOTINIC RECEPTOR; APOLIPOPROTEIN E; APOLIPOPROTEIN E [133-149]; APOLIPOPROTEIN E [141-148]; BUNGAROTOXIN RECEPTOR; NICOTINIC RECEPTOR; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; AMNESIA; ANIMAL CELL; ARTICLE; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; XENOPUS LAEVIS;

ANIMALS; APOLIPOPROTEINS E; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; NICOTINIC ANTAGONISTS; OOCYTES; PEPTIDE FRAGMENTS; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS LAEVIS;

EID: 31144444166     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.095505     Document Type: Article

References (40)

1. Aono M, Bennett ER, Kim KS, Lynch JR, Myers J, Pearlstein RD, Warner DS, and Laskowitz DT (2003) Protective effect of apolipoprotein E-mimetic peptides on N-methyl-D-aspartate excitotoxicity in primary rat neuronal-glial cell cultures. Neuroscience 116:437-445.
2. 3H]Methylcarbamylcholine binding sites in the rat and human brain: relationship to functional nicotinic autoreceptors and alterations in Alzheimer's disease. Prog Brain Res 79:345-352.
3. Bales KR, Dodart JC, DeMattos RB, Holtzman DM, and Paul SM (2002) Apolipoprotein E, amyloid and Alzheimer disease. Mol Intervent 2:363-375, 339.
4. Clay MA, Anantharamaiah GM, Mistry MJ, Balasubramaniam A, and Harmony JA (1995) Localization of a domain in apolipoprotein E with both cytostatic and cytotoxic activity. Biochemistry 34:11142-11151.
5. Colquhoun D and Ogden DC (1988) Activation of ion channels in the frog end-plate by high concentrations of acetylcholine. J Physiol (Lond) 395:131-159.
6. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, and Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (Wash DC) 261:921-923.
7. Croy JE, Brandon T, and Komives EA (2004) Two apolipoprotein E mimetic peptides, ApoE(130-149) and ApoE(141-155)2, bind to LRP1. Biochemistry 43:7328-7335.
8. Crutcher KA, Clay MA, Scott SA, Tian X, Tolar M, and Harmony JA (1994) Neurite degeneration elicited by apolipoprotein E peptides. Exp Neurol 130:120-126.
9. Davies P and Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403.
10. Di Angelantonio S, Costa V, Carloni P, Messori L, and Nistri A (2002) A novel class of peptides with facilitating action on neuronal nicotinic receptors of rat chromaffin cells in vitro: functional and molecular dynamics studies. Mol Pharmacol 61:43-54.
11. Doraiswamy PM (2003) The role of the N-methyl-D-aspartate receptor in Alzheimer's disease: therapeutic potential. Curr Neurol Neurosci Rep 3:373-378.
12. Ellison M, McIntosh JM, and Olivera BM (2003) α-Conotoxins ImI and ImII. Similar α7 nicotinic receptor antagonists act at different sites. J Biol Chem 278:757-764.
13. Friedman G, Froom P, Sazbon L, Grinblatt I, Shochina M, Tsenter J, Babaey S, Yehuda B, and Groswasser Z (1999) Apolipoprotein E-ε4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 52:244-248.
14. Greenfield SA, Day T, Mann EO, and Bermudez I (2004) A novel peptide modulates alpha7 nicotinic receptor responses: implications for a possible trophic-toxic mechanism within the brain. J Neurochem 90:325-331.
15. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, Fish JD, Masliah E, Hopkins PC, Scearce-Levie K, et al. (2003) Carboxyl- terminaltruncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA 100:10966-10971.
16. Howieson DB, Camicioli R, Quinn J, Silbert LC, Care B, Moore MM, Dame A, Sexton G, and Kaye JA (2003) Natural history of cognitive decline in the old. Neurology 60:1489-1494.
17. Jones GM, Sahakian BJ, Levy R, Warburton DM, and Gray JA (1992) Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 108:485-494.
18. Jones S, Sudweeks S, and Yakel JL (1999) Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 22:555-561.
19. Kenakin T (2004) A Pharmacology Primer: Theory, Application and Methods. Elsevier, San Diego.
20. Klein RC and Yakel JL (2004) Inhibition of nicotinic acetylcholine receptors by apolipoprotein E-derived peptides in rat hippocampal slices. Neuroscience 127: 563-567.
21. Laskowitz DT, Thekdi AD, Thekdi SD, Han SK, Myers JK, Pizzo SV, and Bennett ER (2001) Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp Neurol 167:74-85.
22. Levin ED (2002) Nicotinic receptor subtypes and cognitive function. J Neurobiol 53:633-640.
23. Lleo A, Greenberg SM, and Growdon JH (2006) Current pharmacotherapy for Alzheimer's disease. Annu Rev Med, in press.
24. Lynch JR, Wang H, Mace B, Leinenweber S, Warner DS, Bennett ER, Vitek MP, McKenna S, and Laskowitz DT (2005) A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol 192:109-116.
25. Maconochie DJ and Knight DE (1992) Markov modelling of ensemble current relaxations: bovine adrenal nicotinic receptor currents analysed. J Physiol (Lond) 454:155-182.
26. Marques MA and Crutcher KA (2003) Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer's disease. J Mol Neurosci 20:327-337.
27. Marques MA, Tolar M, Harmony JA, and Crutcher KA (1996) A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity. Neuroreport 7:2529-2532.
28. McAdoo JD, Warner DS, Goldberg RN, Vitek MP, Pearlstein R, and Laskowitz DT (2005) Intrathecal administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury. Neurosci Lett 381: 305-308.
29. Michikawa M and Yanagisawa K (1998) Apolipoprotein E4 induces neuronal cell death under conditions of suppressed de novo cholesterol synthesis. J Neurosci Res 54:58-67.
30. Picciotto MR and Zoli M (2002) Nicotinic receptors in aging and dementia. J Neurobiol 53:641-655.
31. Pitas RE, Boyles JK, Lee SH, Foss D, and Mahley RW (1987) Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 917:148-161.
32. Qiu Z, Crutcher KA, Hyman BT, and Rebeck GW (2003) ApoE isoforms affect neuronal N-methyl-D-aspartate calcium responses and toxicity via receptormediated processes. Neuroscience 122:291-303.
33. Raggenbass M and Bertrand D (2002) Nicotinic receptors in circuit excitability and epilepsy. J Neurobiol 53:580-589.
34. Rebeck GW, Reiter JS, Strickland DK, and Hyman BT (1993) Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11:575-580.
35. Tang G, Xie H, Xu L, Hao Y, Lin D, and Ren D (2002) Genetic study of apolipoprotein E gene, alpha-1 antichymotrypsin gene in sporadic Parkinson disease. Am J Med Genet 114:446-449.
36. Tolar M, Keller JN, Chan S, Mattson MP, Marques MA, and Crutcher KA (1999) Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity. J Neurosci 19:7100-7110.
37. Tolar M, Marques MA, Harmony JA, and Crutcher KA (1997) Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J Neurosci 17:5678-5686.
38. Weisgraber KH, Innerarity TL, and Mahley RW (1982) Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 257:2518-2521.
39. White HK and Levin ED (1999) Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology 143: 158-165.
40. Wu J, Kuo YP, George AA, Xu L, Hu J, and Lukas RJ (2004) β-Amyloid directly inhibits human α4β2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. J Biol Chem 279:37842-37851.